Real-life use of apremilast for the treatment of psoriasis in patients with oncological comorbidities: a retrospective descriptive multicentre study in France.

Background: Systemic treatment options for psoriasis are limited for patients with recent neoplasia.

Objectives: We report the real-life use of apremilast (APR) in patients with psoriasis and recent cancer.

Materials & Methods: We conducted a retrospective, multicentre study in five hospitals and among 120 private dermatologists in the north of France from January 2015 to May 2021.

[Treatment of chronic lupus erythematosus with sulfasalazine in 18 patients: reappraisal].

Objective: To evaluate the efficacy and the tolerance of sulfasalazine in the treatment of chronic lupus erythematosus (CLE).

Patients And Methods: We prescribed sulfasalazine (2 g/d) for 18 patients with severe CLE, all of whom had contraindications for or treatment failure with antimalarial drugs and thalidomide. This study analyses their response to treatment, duration of therapy, reasons for stopping, adverse effects, and the influence of the N-acetyltransferase 2 (NAT2) phenotype.